Global Biopharmaceutical Company

Advancing Science to Improve Lives Worldwide

Zhenzhu Pharma is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that address serious unmet medical needs.

15+
Pipeline Programs
50M+
Patients Reached
30+
Countries
2,500+
Employees
FDA Approved Facilities
GMP Certified
ISO 9001:2015
EMA Compliant

Therapeutic Areas

We focus on areas of high unmet medical need where we can make the greatest impact for patients.

Cardiovascular

Developing treatments for heart failure, hypertension, and related conditions.

Learn more

Oncology

Pioneering targeted therapies and immunotherapies for various cancers.

Learn more

Immunology

Creating innovative treatments for autoimmune and inflammatory diseases.

Learn more

Neuroscience

Advancing therapies for neurological and psychiatric disorders.

Learn more

Our Pipeline

A robust portfolio of investigational medicines across multiple therapeutic areas and modalities.

Program
Indication
Preclinical
Phase 1
Phase 2
Phase 3
ZZP-101 Small molecule
Breast Cancer
Active — Phase 3, active
ZZP-205 Monoclonal antibody
Heart Failure
Active — Phase 2, active
ZZP-318 Bispecific antibody
Rheumatoid Arthritis
Active — Phase 1, active
ZZP-422 Gene therapy
Parkinson's Disease
Active — Phase 1, active
ZZP-530 ADC
Lung Cancer
Active — Preclinical, active
ZZP-101 Small molecule
Phase 3, active
Breast Cancer
Progress:
ZZP-205 Monoclonal antibody
Phase 2, active
Heart Failure
Progress:
ZZP-318 Bispecific antibody
Phase 1, active
Rheumatoid Arthritis
Progress:
ZZP-422 Gene therapy
Phase 1, active
Parkinson's Disease
Progress:
ZZP-530 ADC
Preclinical, active
Lung Cancer
Progress:
Scientists working in laboratory
25+
Years of Innovation

Committed to Transforming Patient Lives

Founded in 1998, Zhenzhu Pharma has grown from a small research laboratory to a global biopharmaceutical company with operations across 30 countries.

Our mission is to discover, develop, and deliver innovative medicines that address serious diseases and improve the quality of life for patients worldwide.

Scientific Excellence

World-class R&D capabilities with 500+ scientists

Patient-Centric

Every decision guided by patient needs

Global Reach

Operations in 30+ countries worldwide

Latest News

The latest announcements, press releases, and updates from Zhenzhu Pharma.

AI & R&D Jul 8, 2026

Zhenzhu Launches PearlAI Platform to Accelerate Target Discovery

Our new generative AI platform screened 2.4 million protein–ligand interactions in under 72 hours, prioritizing three oncology targets for preclinical validation.

Read more
Clinical AI Jun 22, 2026

AI-Guided Trial Design Cuts ZZP-205 Enrollment Timeline by 40%

Machine learning models for site selection and patient matching helped open heart failure cohorts faster while maintaining protocol integrity and diversity goals.

Read more
Partnership May 14, 2026

Multi-Year AI Collaboration for De Novo Antibody Design

Zhenzhu partners with a leading computational biology institute to design bispecific candidates for autoimmune disease using foundation models trained on proprietary assay data.

Read more

Partner With Us

Whether you're a healthcare professional, researcher, or potential partner, we'd love to hear from you.